

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/938,497	08/27/2001	Maria K. Boden Wastfelt	012889-086	3731	
21839 7	10/06/2003		EXAM	EXAMINER	
BURNS DOANE SWECKER & MATHIS L L P			LANDSMAN, ROBERT S		
POST OFFICE ALEXANDRIA	EBOX 1404 A, VA 22313-1404		ART UNIT	PAPER NUMBER	
	•		1647	1 +	
			DATE MAILED: 10/06/2003	, /?	

Please find below and/or attached an Office communication concerning this application or proceeding.

	•	Application No.	Applicant(s)			
1	_	09/938,497				
Office Action Summary		·	BODEN WASTFELT ET AL.			
	,	Examiner	Art Unit			
	The MAILING DATE of this communication app	Robert Landsman	1647			
Period fo		sears on the cover sheet with the	correspondence address			
THE I - Exter after - If the - If NO - Failur - Any n	ORTENED STATUTORY PERIOD FOR REPL' MAILING DATE OF THIS COMMUNICATION. misions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period or re to reply within the set or extended period for reply will, by statute eply received by the Office later than three months after the mailing ad patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be to y within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	imely filed  lys will be considered timely.  In the mailing date of this communication.  ED (35 U.S.C. \$ 133)			
1)🖂	Responsive to communication(s) filed on 07 A	August 2003 .				
2a)⊠	This action is <b>FINAL</b> . 2b) Th	is action is non-final.				
3)□ Dispositi	Since this application is in condition for allowed closed in accordance with the practice under on of Claims	ance except for formal matters, p Ex parte Quayle, 1935 C.D. 11,	prosecution as to the merits is 453 O.G. 213.			
4)⊠	Claim(s) 2-7 and 9-13 is/are pending in the ap	pplication.				
4	4a) Of the above claim(s) <u>2-7,10 and 11</u> is/are	withdrawn from consideration.				
5)	Claim(s) is/are allowed.					
6)⊠	Claim(s) <u>9,12 and 13</u> is/are rejected.					
7)🖂	Claim(s) 9,12 and 13 is/are objected to.					
	Claim(s) are subject to restriction and/or on Papers	r election requirement.				
9)⊠ ⊺	The specification is objected to by the Examiner	r.				
	The drawing(s) filed on is/are: a)☐ accep		miner.			
	Applicant may not request that any objection to the					
11) 🔲 T	he proposed drawing correction filed on					
	If approved, corrected drawings are required in rep		•			
12) <u></u> ⊤	he oath or declaration is objected to by the Exa	aminer.				
Priority u	nder 35 U.S.C. §§ 119 and 120					
13)🛛 .	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	a)-(d) or (f).			
	☑ All b) ☐ Some * c) ☐ None of:		, , , ,			
	1. Certified copies of the priority documents	s have been received.				
:	2. Certified copies of the priority documents	s have been received in Applicati	ion No. <u>09/276,141</u> .			
;	<ol> <li>Copies of the certified copies of the prior application from the International Bur</li> </ol>	ity documents have been receive eau (PCT Rule 17.2(a)).	ed in this National Stage			
	ee the attached detailed Office action for a list of					
	cknowledgment is made of a claim for domestic					
15)⊠ A	The translation of the foreign language pro- cknowledgment is made of a claim for domestic	visional application has been rec c priority under 35 U.S.C. §§ 120	eived. ) and/or 121.			
Attachment(	•					
2) X Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	/ (PTO-413) Paper No(s) Patent Application (PTO-152)			
S. Patent and Trad TOL-326 (Re		ion Summary	Part of Paper No. 13			

Application/Control Number: 09/938,497

Art Unit: 1647

### **DETAILED ACTION**

### 1. Formal Matters

- A. Amendment C, filed 8/7/03, has been entered into the record.
- B. Amendment B, filed 6/12/03, has been entered into the record.
- C. Claims 2-7 and 9-13 are pending in this Office Action. Claims 2-7 and 10-11 have been withdrawn as being drawn to non-elected subject matter. Therefore, claims 9, 12 and 13 are the subject of this Office Action. Claims
- D. All Statutes under 35 USC not found in this Office Action can be found, cited in full, in a previous Office Action.
- E. Though not objected to at this time, it is suggested that the nucleic acid sequence of claim 6 be identified only by the appropriate sequence identifier as set forth in the "Sequence Listing" as required by 37 CFR 1.821(d). Applicants are requested to remove the recitation of the sequence from the claim. Reciting the sequence itself is awkward, difficult to consider, and increases the possibility of printer errors. No objection is being made at this time since claim 6 is drawn to a non-elected invention. However, if this claim is rejoined upon the finding of any allowable subject matter, this issue will need to be addressed.

## 2. Oath/Declaration

A. The objection to the Declaration has been withdrawn in view of Applicants submission of a new Declaration with initialed changes.

# 3. Specification

A. The specification is objected to since neither Figures 8-11, nor the Brief Description of the Drawings for these Figures, provide sequence identifiers. If new SEQ ID NOs are added, then Applicants are required to submit a new sequence listing and disk, as well as a statement that both the disk and sequence listing are identical and contain no new matter. Furthermore, the sequences on page 11, lines 27-35 and page 12, lines 4-6 also need sequence identifiers. See 37 CFR 1.821-1.825.

## 4. Claim Objections

A. The objection to claim 9 has been withdrawn in view of Applicants' amendment to the claim to recite "A pharmaceutical." However, new objections to claim 9 appear below.

Application/Control Number: 09/938,497 Page 3

Art Unit: 1647

B. Claim 9 is objected to since the syntax could be improved by replacing the word "a" in

"comprising a fibrinogen" with "the."

C. Claims 9, 12 and 13 are objected to since claim 12 recites "derived from." The syntax could be

improved by replacing this phrase with, for example, "obtained from" or "isolated from." Claims 9 and 13

are objected to since they depend from claim 12.

5. Claim Rejections - 35 USC § 102

A. The rejection of claims 9, 12 and 13 under 35 USC 102(b) as being anticipated by Palma et al.

has been withdrawn in view of Applicants' argument that the present invention receives priority at least to

PCT/SE93/00759. The effective U.S. filing date is 5/23/94. Applicants have amended the first line of the

specification to reflect this priority. Therefore, the present invention deserves priority prior to the 1998

publication date of Palma et al.

B. Claims 9, 12 and 13 remain rejected under 35 USC 102(b) as being anticipated by Boden et al.

Applicants argue that the present invention deserves priority as far back as its swedish application

9202720-0, filed 9/21/92. However, the present application is a CON of PCT/SE93/00759 and is not the

National Stage entry. Therefore, the effective U.S. filing date of the present application is 5/23/94, the

filing date of U.S. Application 08/244,229. The Boden et al. reference was published 4/92, more than 1

year prior to the effective U.S. filing date and is, therefore, considered prior art under 35 USC 102(b).

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in

37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX

MONTHS from the mailing date of this final action.

Application/Control Number: 09/938,497

Art Unit: 1647

# Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Landsman whose telephone number is (703) 306-3407. The examiner can normally be reached on Monday - Friday from 8:00 AM to 5:00 PM (Eastern time) and alternate Fridays from 8:00 AM to 5:00 PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Official papers filed by fax should be directed to (703) 308-4242. Fax draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Robert Landsman, Ph.D. Patent Examiner Group 1600 October 03, 2003

ROBERT LANDSMAN
PATENT EXAMINER

Page 4